Analyst Price Target Update on Alkermes plc (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS): The mean estimate for the short term price target for Alkermes plc (NASDAQ:ALKS) stands at $57.8 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $77 while the lower price target estimate is at $50.

Many analysts have stated their opinion on the company shares. Evercore ISI Group initiates coverage on Alkermes plc (NASDAQ:ALKS). The current rating of the shares is Buy, according to the research report released by the firm. The rating by the firm was issued on May 26, 2016. Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Mitchell Paul J, director of Alkermes Plc., had unloaded 2,000 shares at an average price of $44.97 in a transaction dated on June 6, 2016. The total value of the transaction was worth $89,940.

Alkermes plc (NASDAQ:ALKS) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.18 points or 0.42% at $42.47 with 964,060 shares getting traded. Post opening the session at $42.5, the shares hit an intraday low of $42.29 and an intraday high of $43.39 and the price was in this range throughout the day. The company has a market cap of $6,420 million and the number of outstanding shares have been calculated to be 151,165,400 shares. The 52-week high of Alkermes plc (NASDAQ:ALKS) is $80.71 and the 52-week low is $27.14.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.